HCM vs PAYC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: PAYC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCM and PAYC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCM and PAYC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

HUTCHMED (China) Limited trades on Nasdaq as ADSs under HCM, on the Hong Kong Stock Exchange as stock code 13, and on London's AIM market. It discovers and develops targeted oncology and immunology therapies in China and increasingly commercializes them globally through partners. Its marketed portfolio includes fruquintinib (sold as ELUNATE in China with Eli Lilly and as FRUZAQLA outside China with Takeda), surufatinib (SULANDA) for neuroendocrine tumors, and savolitinib (ORPATHYS) partnered with AstraZeneca. A separate Other Ventures segment, mainly prescription drug distribution in China, contributed ~$116 million of revenue in the first half of 2026 and is a lower-margin, non-innovative business that inflates headline revenue relative to the drug franchise.

Full HCM guide

Paycom Software, Inc. provides a cloud-based human capital management platform that US employers use to run payroll and related HR functions from a single database. Its product suite spans payroll, tax management, time and attendance, benefits administration, talent acquisition, and HR analytics, all built on one system of record so data is entered once and flows everywhere. Paycom sells primarily to the mid-market, businesses with roughly 50 to 5,000 employees, and competes with the likes of ADP, Paychex, Paylocity, Workday, UKG, and Ceridian's Dayforce. The economics are attractive: recurring and other revenues made up about 95% of total revenue in 2025, the company carries no debt, and adjusted EBITDA margins run in the low-to-mid 40s percent, among the highest in the payroll software group.

Full PAYC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HCM drivers: ATTC platform licensing as the value unlock; China commercial rebound and fruquintinib's geographic spread.
• PAYC drivers: Sticky, high-margin recurring revenue; Automation and the Beti bet.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does. For PAYC, the clearest risk is decelerating growth: Paycom has slowed from 20%-plus expansion in its hypergrowth years to high single digits, and its 2026 guidance disappointed some investors, so any further slowdown could pressure the stock, which fell sharply in 2025.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HCM if you believe its drivers more; PAYC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCM and PAYC guides.

HCM. The headline revenue number is misleading on its own because ~$116 million of first-half 2026 revenue came from the low-margin Other Ventures drug distribution segment rather than innovative medicines; the oncology and immunology franchise generated ~$162.3 million, of which ~$40.9 million was milestone, royalty and R&D service income including an ~$18.1 million payment from Eli Lilly. Profitability is genuine but slim, with R&D of ~$78.8 million in the half consuming most of the gross profit. Because net cash covers roughly half the market value, valuation multiples on the operating business look far lower than a screener showing price-to-sales on the consolidated figure would suggest.

PAYC. Figures are approximate and tied to the asOf date; confirm current numbers and guidance before making any decision. Paycom sits in an unusual spot for software: clearly profitable and cash-generative, but growing far slower than it once did. That means the valuation debate hinges less on revenue acceleration and more on whether high margins, retention, and capital returns justify the price, so where the growth rate stabilizes matters more than any single quarter.

Headline figures (approximate, September 2026): HCM shows market capitalization ~$2.4B (ADS ~$14, ~173M ADSs, each ADS = 5 ordinary shares), revenue (ttm) ~$549M (FY2025 ~$548.5M; H1 2026 ~$278.3M vs ~$277.7M in H1 2025), net income attributable (ttm) ~$18M (H1 2026 ~$15.9M; the ~$455M H1 2025 figure was mostly a one-off SHPL divestment gain), cash and short-term investments ~$1.37B at June 30, 2026, against ~$95M of bank borrowings; PAYC shows revenue trend 2025 revenue was roughly $2.05 billion, up about 9% year over year, a deceleration from prior double-digit growth; 2026 guidance points to mid-to-high single-digit growth, profitability Consistently GAAP-profitable with high margins; adjusted EBITDA margins run in the low-to-mid 40s percent, among the strongest in payroll software, recurring revenue mix About 95% of total revenue is recurring and other (subscription-like), which supports predictable results, balance sheet No debt and strong free cash flow, funding a modest and growing dividend plus share repurchases.

HCM and PAYC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HCM and PAYC exposure against your real portfolio. It is not an investment adviser.